IL-17 receptor A antigen binding proteins
View Patent ↗The present invention relates to IL-17 Receptor A antigen binding proteins, such as antibodies, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation.
1. An isolated antibody, comprising a light chain variable domain comprising SEQ ID NO:40 and a heavy chain variable domain comprising SEQ ID NO:14, wherein said antibody specifically binds human IL-17 receptor A.
2. An isolated antibody, comprising a light chain CDR1 comprising SEQ ID NO:224, a light chain CDR2 comprising SEQ ID NO:225, a light chain CDR3 comprising SEQ ID NO:226, a heavy chain CDR1 comprising SEQ ID NO:146, a heavy chain CDR2 comprising SEQ ID NO:147, and a heavy chain CDR3 comprising SEQ ID NO:148, wherein said antibody specifically binds human IL-17 receptor A.
3. The antibody of either of claim 1 or 2 , wherein said antibody is selected from the group consisting of:
a. a human antibody;
b. a humanized antibody;
c. a chimeric antibody;
d. a recombinant antibody;
e. a single chain antibody;
f. a diabody;
g. a triabody;
h. a tetrabody;
i. a Fab fragment;
j. a F(ab′)2 fragment;
k. an IgD antibody;
l. an IgE antibody;
m. an IgM antibody;
n. an IgG1 antibody;
o. an IgG2 antibody;
P. an IgG3 antibody; and
q. an IgG4 antibody.
4. A pharmaceutical composition, comprising the antibody of claim 3 .
5. The antibody of claim 3 , wherein said antibody is conjugated to a chemical moiety selected from the group consisting of:
(a) polyethylene glycol; and
(b) human serum albumin.
6. An isolated polypeptide, comprising a light chain variable domain comprising SEQ ID NO:40 and a heavy chain variable domain comprising SEQ ID NO:14, wherein said polypeptide specifically binds human IL-17 receptor A.
7. An isolated polypeptide, comprising a light chain CDR1 comprising SEQ ID NO:224, a light chain CDR2 comprising SEQ ID NO:225, a light chain CDR3 comprising SEQ ID NO:226, a heavy chain CDR1 comprising SEQ ID NO:146, a heavy chain CDR2 comprising SEQ ID NO:147, and a heavy chain CDR3 comprising SEQ ID NO:148, wherein said polypeptide specifically binds human IL-17 receptor A.
8. A pharmaceutical composition, comprising the polypeptide of claims 6 or 7 .
9. An isolated antibody, comprising an IgG2 human monoclonal antibody comprising a light chain CDR1 comprising SEQ ID NO:224, a light chain CDR2 comprising SEQ ID NO:225, a light chain CDR3 comprising SEQ ID NO:226, a heavy chain CDR1 comprising SEQ ID NO:146, a heavy chain CDR2 comprising SEQ ID NO:147, and a heavy chain CDR3 comprising SEQ ID NO:148, wherein said antibody specifically binds human IL-17 receptor A.
10. The antibody of claim 9 , wherein said antibody comprises a light chain variable domain comprising SEQ ID NO:40 and a heavy chain variable domain comprising SEQ ID NO:14.
11. The antibody of claim 10 , wherein said antibody comprises a heavy chain sequence comprising SEQ ID NO:427 and a light chain sequence comprising SEQ ID NO:429.
12. A pharmaceutical composition, comprising an IgG2 human monoclonal antibody comprising a light chain CDR1 comprising SEQ ID NO:224, a light chain CDR2 comprising SEQ ID NO:225, a light chain CDR3 comprising SEQ ID NO:226, a heavy chain CDR1 comprising SEQ ID NO:146, a heavy chain CDR2 comprising SEQ ID NO:147, and a heavy chain CDR3 comprising SEQ ID NO:148, wherein said antibody specifically binds human IL-17 receptor A.
13. The antibody of claim 9 , 10 , or 11 , wherein said antibody is conjugated to a chemical moiety selected from the group consisting of:
(a) polyethylene glycol; and
(b) human serum albumin.
14. An isolated antibody, comprising SEQ ID NO:427 and SEQ ID NO:429.
15. A pharmaceutical composition, comprising the antibody of claim 14 .
16. The antibody of claim 14 , wherein said antibody is conjugated to a chemical moiety selected from the group consisting of:
(a) polyethylene glycol; and
(b) human serum albumin.
17. A pharmaceutical composition, comprising an antibody comprising a light chain variable domain comprising SEQ ID NO:40 and a heavy chain variable domain comprising SEQ ID NO:14.
18. A pharmaceutical composition, comprising an antibody comprising a light chain CDR1 comprising SEQ ID NO:224, a light chain CDR2 comprising SEQ ID NO:225, a light chain CDR3 comprising SEQ ID NO:226, a heavy chain CDR1 comprising SEQ ID NO:146, a heavy chain CDR2 comprising SEQ ID NO:147, and a heavy chain CDR3 comprising SEQ ID NO:148, wherein said antibody specifically binds human IL-17 receptor A.
19. A pharmaceutical composition, comprising an IgG2 human monoclonal antibody comprising a light chain variable domain comprising SEQ ID NO:40 and a heavy chain variable domain comprising SEQ ID NO:14.
20. A pharmaceutical composition, comprising an IgG2 human monoclonal antibody comprising a heavy chain sequence comprising SEQ ID NO:427 and a light chain sequence comprising SEQ ID NO:429.
21. The antibody of claim 1 , wherein said antibody is a human antibody.
22. The antibody of claim 21 , wherein said antibody is a monoclonal antibody.
23. The antibody of claim 1 , wherein said antibody is a humanized antibody.
24. The antibody of claim 23 , wherein said antibody is a monoclonal antibody.
25. The antibody of claim 1 , wherein said antibody is a chimeric antibody.
26. The antibody of claim 25 , wherein said antibody is a monoclonal antibody.
27. The antibody of claim 2 , wherein said antibody is a human antibody.
28. The antibody of claim 27 , wherein said antibody is a monoclonal antibody.
29. The antibody of claim 2 , wherein said antibody is a humanized antibody.
30. The antibody of claim 29 , wherein said antibody is a monoclonal antibody.
31. The antibody of claim 2 , wherein said antibody is a chimeric antibody.
32. The antibody of claim 31 , wherein said antibody is a monoclonal antibody.